Suppr超能文献

肝细胞癌:基于胆汁酸的新认识和治疗策略(综述)。

Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review).

机构信息

Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110122, P.R. China.

104K class 87, The Second Clinical College, China Medical University, Shenyang, Liaoning 110122, P.R. China.

出版信息

Int J Oncol. 2022 Oct;61(4). doi: 10.3892/ijo.2022.5407. Epub 2022 Aug 5.

Abstract

Bile acids (BAs) are the major components of bile and products of cholesterol metabolism. Cholesterol is catalyzed by a variety of enzymes in the liver to form primary BAs, which are excreted into the intestine with bile, and secondary BAs are formed under the modification of the gut microbiota. Most of the BAs return to the liver via the portal vein, completing the process of enterohepatic circulation. BAs have an important role in the development of hepatocellular carcinoma (HCC), which may participate in the progression of HCC by recognizing receptors such as farnesoid X receptor (FXR) and mediating multiple downstream pathways. Certain BAs, such as ursodeoxycholic acid and obeticholic acid, were indicated to be able to delay liver injury and HCC progression. In the present review, the structure and function of BAs were introduced and the metabolism of BAs and the process of enterohepatic circulation were outlined. Furthermore, the mechanisms by which BAs participate in the development of HCC were summarized and possible strategies for targeting BAs and key sites of their metabolic processes to treat HCC were suggested.

摘要

胆汁酸(BAs)是胆汁的主要成分和胆固醇代谢的产物。胆固醇在肝脏中被多种酶催化形成初级 BAs,与胆汁一起被排泄到肠道,在肠道微生物群的修饰下形成次级 BAs。大多数 BAs 通过门静脉返回肝脏,完成肠肝循环过程。BAs 在肝细胞癌(HCC)的发展中起重要作用,可能通过识别法尼醇 X 受体(FXR)等受体并介导多种下游途径参与 HCC 的进展。某些 BAs,如熊去氧胆酸和奥贝胆酸,被证明能够延缓肝损伤和 HCC 的进展。在本综述中,介绍了 BAs 的结构和功能,并概述了 BAs 的代谢和肠肝循环过程。此外,总结了 BAs 参与 HCC 发展的机制,并提出了针对 BAs 及其代谢过程关键部位的可能治疗 HCC 的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7c40/9450808/79cb8b43fba5/IJO-61-4-05407-g00.jpg

相似文献

1
Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review).
Int J Oncol. 2022 Oct;61(4). doi: 10.3892/ijo.2022.5407. Epub 2022 Aug 5.
3
Effect of different bile acids on the intestine through enterohepatic circulation based on FXR.
Gut Microbes. 2021 Jan-Dec;13(1):1949095. doi: 10.1080/19490976.2021.1949095.
4
Comparison of bile acids profiles in the enterohepatic circulation system of mice and rats.
J Steroid Biochem Mol Biol. 2022 Jun;220:106100. doi: 10.1016/j.jsbmb.2022.106100. Epub 2022 Mar 25.
5
The gut microbiome-bile acid axis in hepatocarcinogenesis.
Biomed Pharmacother. 2021 Jan;133:111036. doi: 10.1016/j.biopha.2020.111036. Epub 2020 Nov 28.
7
Bile Acid Physiology.
Ann Hepatol. 2017 Nov;16(Suppl. 1: s3-105.):s4-s14. doi: 10.5604/01.3001.0010.5493.
8
Increased bile acids in enterohepatic circulation by short-term calorie restriction in male mice.
Toxicol Appl Pharmacol. 2013 Dec 15;273(3):680-90. doi: 10.1016/j.taap.2013.10.020. Epub 2013 Oct 29.
9
Cross-talk between bile acids and intestinal microbiota in host metabolism and health.
J Zhejiang Univ Sci B. 2015 Jun;16(6):436-46. doi: 10.1631/jzus.B1400327.

引用本文的文献

1
A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis.
J Exp Clin Cancer Res. 2025 Aug 21;44(1):246. doi: 10.1186/s13046-025-03505-5.
2
The role of bile acid metabolism-related genes in prognosis assessment of hepatocellular carcinoma and identification of NPC1 as a biomarker.
Front Endocrinol (Lausanne). 2025 May 29;16:1588529. doi: 10.3389/fendo.2025.1588529. eCollection 2025.
4
Metabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis.
JHEP Rep. 2024 May 15;6(8):101119. doi: 10.1016/j.jhepr.2024.101119. eCollection 2024 Aug.
5
Alteration of serum bile acid profiles of HBV-related hepatocellular carcinoma identified by LC-MS/MS.
J Cancer Res Clin Oncol. 2024 Mar 25;150(3):157. doi: 10.1007/s00432-024-05686-6.
6
Association between blood lipid levels and the risk of liver cancer: a systematic review and meta-analysis.
Cancer Causes Control. 2024 Jun;35(6):943-953. doi: 10.1007/s10552-024-01853-9. Epub 2024 Feb 20.
8
Hepatocellular loss of mTOR aggravates tumor burden in nonalcoholic steatohepatitis-related HCC.
Neoplasia. 2023 Dec;46:100945. doi: 10.1016/j.neo.2023.100945. Epub 2023 Nov 15.
9
The roles of gut microbiota and its metabolites in diabetic nephropathy.
Front Microbiol. 2023 Jul 27;14:1207132. doi: 10.3389/fmicb.2023.1207132. eCollection 2023.
10
The role of bile acid metabolism in the occurrence and development of NAFLD.
Front Mol Biosci. 2022 Dec 15;9:1089359. doi: 10.3389/fmolb.2022.1089359. eCollection 2022.

本文引用的文献

1
Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation.
Nat Commun. 2022 Jun 14;13(1):3419. doi: 10.1038/s41467-022-31141-6.
2
Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation.
Hepatology. 2023 Apr 1;77(4):1164-1180. doi: 10.1002/hep.32608. Epub 2022 Jul 7.
3
The role of bile acids in carcinogenesis.
Cell Mol Life Sci. 2022 Apr 16;79(5):243. doi: 10.1007/s00018-022-04278-2.
5
A Recent Ten-Year Perspective: Bile Acid Metabolism and Signaling.
Molecules. 2022 Mar 18;27(6):1983. doi: 10.3390/molecules27061983.
6
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.
Nat Rev Gastroenterol Hepatol. 2022 Jul;19(7):432-450. doi: 10.1038/s41575-021-00566-7. Epub 2022 Feb 14.
7
Hippo signalling in the liver: role in development, regeneration and disease.
Nat Rev Gastroenterol Hepatol. 2022 May;19(5):297-312. doi: 10.1038/s41575-021-00571-w. Epub 2022 Jan 21.
8
Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles.
J Clin Med. 2021 Dec 21;11(1):4. doi: 10.3390/jcm11010004.
9
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.
Front Oncol. 2021 Dec 15;11:760971. doi: 10.3389/fonc.2021.760971. eCollection 2021.
10
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
J Hepatol. 2022 Feb;76(2):446-457. doi: 10.1016/j.jhep.2021.09.007. Epub 2021 Sep 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验